Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
A phase 3 trial of Pembrolizumab, Oxaliplatin, Bevacizumab and Cetuximab in colorectal cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) is a phase 3 interventional study registered as NCT05239741 by Merck Sharp & Dohme LLC, with 100 participants enrolled, started 2022-04-02 and due to reach its primary completion in 2028-09-19. Interventions recorded: Pembrolizumab, Oxaliplatin, Leucovorin, 5-fluorouracil, Irinotecan and Bevacizumab.
Similar pages
not linked directly; found by shared links- TrialA Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Shares Oxaliplatin, Cetuximab, Bevacizumab, Colorectal cancer and the tag pipeline.
- TrialA Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
Shares Oxaliplatin, Bevacizumab, Colorectal cancer and the tag pipeline.
- TrialAK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Shares Oxaliplatin, Bevacizumab, Colorectal cancer and the tag pipeline.
- TrialS-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Shares Bevacizumab, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Shares Oxaliplatin, Cetuximab, Colorectal cancer and the tag pipeline.
- TrialA Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Shares Cetuximab, Bevacizumab, Colorectal cancer and the tag pipeline.
- TrialKEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Shares Cetuximab, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Shares Oxaliplatin, Cetuximab, Pembrolizumab and the tag pipeline.